/

In

VCRO express

VCRO express

Congratulation! A Phase I/IIa IND of the anti-cancer combination therapy was granted by the US FDA.

•

Nov 9
VCRO express

Congratulations! Phase III pivotal study CSR for Ischemic stroke recovery Chinese traditional new medicine was granted by TFDA!

•

May 10
VCRO express

Congratulations! Phase IV Post-Marketing research study CSR for pain control drug was granted by TFDA

•

May 2
VCRO express

Congratulations!Approval was granted by TFDA for the GCP inspection of a multi-center phase II/III vaccine pivotal study with over a thousand subjects

•

Apr 17
VCRO express

Congratulations! VCRO submitted an IND for a new formulation product in pain control was accepted by the TFDA

•

Mar 24
VCRO express

Congratulations! Phase III pivotal study CSR for pain control new drug was granted by TFDA

•

Oct 4
VCRO express

Congratulations! Orphan drug designation for cell therapy was granted by the US FDA

•

Sep 30
VCRO express

Congratulations! VCRO submitted an IND for a novel product in pain control was accepted by the US FDA

•

Aug 23
VCRO express

Congratulations! A Phase I/IIa IND of small molecule drug for brain tumor treatment was approved for clinical-go by the USA FDA

•

Aug 9
VCRO express

Congratulations! More Bridging Study Evaluation (BSE) Waivers granted by TFDA

•

Sep 7